Survodutide: Trial Evidence, Approval Timeline & What's Actually Legal

Survodutide is Boehringer Ingelheim's glucagon/GLP-1 dual agonist — strong Phase 3 obesity results and breakthrough status in liver disease, but not approved anywhere yet. Understand the evidence and the timeline. This page is informational and does not diagnose, prescribe, or recommend therapies.

Looking for clinics by city? Explore peptide clinics in Miami , Los Angeles, and New York to compare verified providers by treatment focus.

Recovery peptide users often compare BPC-157 and TB-500, while metabolic health users usually cross-reference semaglutide.

Common contexts

Clinics may reference this peptide within broader wellness or longevity pathways.
Use this directory page to compare profile transparency and consultation options.

Safety information

This directory is informational and does not provide medical advice.
Always discuss suitability and risk profile directly with a licensed clinician.

Quick summary

Survodutide is a glucagon/GLP-1 dual receptor agonist developed by Boehringer Ingelheim with Zealand Pharma — glucagon, not GIP, is its second mechanism, unlike tirzepatide.
Phase 3 SYNCHRONIZE-1 reported up to 16.6% average weight loss at 76 weeks (placebo 3.2%), with 85% of participants losing at least 5% of body weight.
Its liver-disease programme is the standout: FDA Breakthrough Therapy and Fast Track designations in MASH, EMA PRIME status, and Phase 3 liver readouts due later in 2026.
It is not approved anywhere; obesity approval is projected around 2027.
GLP-1 and glucagon-receptor medicines are not currently prohibited by WADA, but athletes should always verify the current list.
This page is informational only — it does not diagnose, prescribe, recommend survodutide, or provide dosing guidance.

Evidence at a glance

A scannable summary of what the current research and UK/US regulatory position actually show. Educational only — not medical advice, and no dosing guidance.

Evidence: Phase 3 obesity evidence: SYNCHRONIZE-1 met both co-primary endpoints with up to 16.6% average weight loss at 76 weeks (placebo 3.2%); 85.1% achieved ≥5% loss. MASH/MASLD programme carries FDA Breakthrough Therapy status; Phase 3 liver readouts (LIVERAGE) due later in 2026.
Human data: Extensive and ongoing — full Phase 3 programmes in obesity and liver disease.
UK regulatory status: Not a licensed UK medicine — the MHRA has not authorised survodutide. Any UK-sold product is an unlicensed grey-market import.
US regulatory status: Not FDA-approved. Breakthrough Therapy and Fast Track designations in MASH accelerate review but confer no approval. Obesity approval projected around 2027. Not available through legitimate compounding.
Anti-doping (sport): Not currently named on the WADA prohibited list; the list changes annually and catch-all provisions exist — tested athletes should verify current status.

Last reviewed 14 August 2026. Regulatory status can change — always confirm the current position with a qualified clinician.

Claim vs evidence

Common marketing and internet claims about Survodutide, set against what the research actually shows. Educational only — not medical advice.

Claim	Human evidence	What the evidence shows
“Survodutide beats semaglutide and tirzepatide”	No head-to-head	No head-to-head trial exists. Its 16.6% average sits in the range of approved medicines' trials, but populations and designs differ — cross-trial percentage comparisons are unreliable by construction.
“It cures fatty liver disease”	Promising, unfinished	SYNCHRONIZE-MASLD showed liver-fat normalisation in about 60% of treated participants, and the MASH programme holds breakthrough designations — but the pivotal Phase 3 liver outcomes had not read out as of mid-2026. Promising is not proven.
“You can buy survodutide online”	Not approved	No regulator has approved it and no legitimate pharmacy can supply it. Online vials are unregulated research chemicals — identity, dose, and purity unverifiable.

Clear intro

Survodutide is the quiet one of the next-generation trio — less hyped than retatrutide or CagriSema, but with a liver-disease programme none of the others can match. Understanding what it is, and that it cannot legitimately be bought, is the whole story for 2026.

Who this is for

This page is for people tracking next-generation weight-management medicines, anyone researching MASH treatment pipelines, and anyone offered 'survodutide' online who should know no legitimate supply exists.

What to ask before choosing a clinic

Survodutide is not approved — if it's being mentioned, is that pipeline education or is someone selling it?
Would approved options meet my weight-management goals today?
If liver health is my concern, what approved and trial-based routes exist right now?

Pricing and red flags

Nothing legitimate is for sale. Judge any vendor price accordingly — it is the price of an unverifiable chemical, not a medicine.

Any sale of 'survodutide' — no approved or compounded product exists anywhere.
Quoting SYNCHRONIZE trial percentages as if they apply to grey-market vials.
Implying its breakthrough designations mean it is approved — they accelerate review, nothing more.

What is Survodutide?

Survodutide is a once-weekly injectable peptide that activates both the glucagon receptor and the GLP-1 receptor. The GLP-1 side suppresses appetite like semaglutide; the glucagon side is intended to raise energy expenditure and act directly on liver fat — which is why survodutide is being developed in parallel for obesity and for MASH (metabolic dysfunction-associated steatohepatitis, the liver disease formerly called NASH). Its Phase 3 obesity trial SYNCHRONIZE-1 met both co-primary endpoints, and its liver programme carries FDA Breakthrough Therapy and Fast Track designations plus EMA PRIME status. It remains investigational everywhere, with obesity approval projected around 2027.

How it works

Dual agonism spreads the metabolic work across two hormone systems: GLP-1 reduces intake, glucagon increases expenditure and mobilises liver fat. In SYNCHRONIZE-MASLD, six in ten participants with MASLD and obesity or overweight reached liver-fat normalisation after 48 weeks — the clearest sign that the glucagon component does something distinctive. The obesity numbers (up to 16.6% at 76 weeks) sit below CagriSema's and retatrutide's headline figures, but cross-trial comparisons mislead, and survodutide's liver data may prove the more important differentiator.

Typical use cases

Weight-management pipeline discussions, as one of the leading next-generation dual agonists.
Liver-health contexts — it is among the most advanced drug candidates for MASH.
Comparisons with tirzepatide and retatrutide, where its glucagon mechanism is the distinguishing feature.

Cost overview

No approved product exists, so there is no legitimate price. Any 'survodutide' sold online is an unregulated research chemical. Legitimate access today means clinical-trial enrolment, which costs nothing. See the peptide therapy cost guide.

What to expect from clinics

A credible provider should state plainly that survodutide is unapproved and unavailable outside trials.
Expect approved options — semaglutide, tirzepatide — to be discussed first for weight management.
Liver-focused claims should point to trial participation, not product sales — there is no legitimate survodutide supply.

Safety considerations

Trial tolerability has been broadly consistent with incretin-class medicines — predominantly gastrointestinal effects, dose-titrated. That data describes pharmaceutical product under clinical supervision. Grey-market vials have no verified identity, dose, or sterility, and the glucagon mechanism makes casual self-experimentation a particularly poor idea. This page does not recommend survodutide and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.

Frequently asked questions about Survodutide

Is survodutide approved?

No. It is investigational everywhere. Phase 3 trials are ongoing or reading out through 2026, and approval for the obesity indication is projected around 2027. Its FDA Breakthrough Therapy and Fast Track designations speed up review — they are not approval.

How does survodutide differ from tirzepatide?

Both pair GLP-1 agonism with a second mechanism, but the second hormone differs: tirzepatide adds GIP, survodutide adds glucagon. The glucagon component is designed to raise energy expenditure and reduce liver fat, which is why survodutide is also a leading MASH candidate.

How much weight loss did survodutide show?

SYNCHRONIZE-1 reported up to 16.6% average weight loss at 76 weeks versus 3.2% for placebo, with 85.1% of participants losing at least 5% of body weight. Those numbers describe supervised trial conditions, not grey-market use.

Can I get survodutide now?

Legitimately, only inside a clinical trial. No approved product or lawful compounded version exists, so anything sold online is an unregulated research chemical. Approved alternatives are available through licensed providers today.

Does Peptide Clinic Finder sell or recommend survodutide?

No. Peptide Clinic Finder is an informational directory. We do not sell survodutide, provide medical advice, or recommend its use — we explain the real approval status and evidence so you can make informed decisions with a licensed clinician.

Related comparisons: Survodutide vs Tirzepatide.

Next step

Compare Providers and Next Steps

If you are considering this treatment, compare providers, review your options, and choose the path that best fits your goals and preferred level of care.

Compare Providers Get Matched Browse city clinics

Related Survodutide pages

Move from peptide research into clinic comparisons, guides, and matching.

LiveNow Longevity Survodutide vs Tirzepatide Menon Health Extend Medical 360 MD Austin Anderson Longevity Clinic Aspire Rejuvenation Clinic

Not sure whether local clinics or online options are the better fit? compare providers or use our matching tool to find the right next step. If you want a broader market view first, find a peptide clinic near you.

Clinics offering Survodutide

No clinics are currently tagged with this peptide. Explore related goals, conditions, and comparisons below.

Explore clinics by city

Miami peptide clinics Los Angeles peptide clinics New York peptide clinics All US locations

What to do next

Move from treatment research into provider comparison by choosing the next step that fits your buying journey. Some users want to compare programmes first, while others want a faster route into matched options or local clinic discovery.

Compare Providers Get Matched Miami clinics Los Angeles clinics New York clinics